SalMar ASA (SALM)
Verdict history · SALM
Every call Verdix has made on SALM.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
See methodology for how verdicts are produced. Full track record →
The panel’s case against SALM — and where they disagree.
The case against outweighs the case for at today's price.
OSL · Consumer Staples · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
SellMEDIUM confidence
Why
All five voices land Bearish on SalMar at 526.5 NOK: the balance sheet is stretched, negative estimate revisions are piling up, and the V-shaped salmon-price recovery is already priced in but not yet delivered. The only debate is whether the stock is merely overvalued or whether the debt load makes the payoff structure genuinely asymmetric to the downside, with a weekly close above 540 as the trigger that could flip the entire bearish structure.Level to watch
Key support 520−1.2% from 526.5
Next catalyst
Trigger to flip bearish structure: A weekly close above 540 on expanding volume would be the first credible signal that the monthly Stage 4 downtrend is transitioning, invalidating the bearish technical base.The panel's take
Verdict: SELL · Conviction: MEDIUM · Last price: 526.5
Panel: 0 Bullish · 1 Neutral · 4 Bearish → SELL
What changed since 2026-08-18:
- Price: 517.5 → 526.5 (+1.74%)
- Panel: 0 of 6 → 0 of 5 now Bullish — composition also changed: added The Activist Catalyst; removed The Macro Opportunist, The Margin-of-Safety Hunter
- Trigger: A weekly close above 540 (EMA50) on expanding volume — the technical trigger the technical scout named for credible Stage-1 transition — would break the bearish structure. Absent that, the downtrend governs.
- Verdict: SELL (unchanged)
The prior panel delivered a high-conviction SELL at 517.5; this panel stays Bearish at 526.5 but conviction drops to MEDIUM. The shift reflects a marginally better technical picture (the embryonic weekly MACD crossover) and the exit of two bearish voices, replaced by the Activist Catalyst who is decisively Bearish but whose conviction ceiling is capped by the business-model objection rather than a specific near-term catalyst. The price drifted up 1.7% while the fundamental concerns around leverage, negative revisions, and the untested V-shaped recovery remained static, compressing what little risk cushion existed.
Four of five voices vote Bearish: the business is a stretched-balance-sheet cyclical pricing in a V-shaped recovery that negative estimate revisions are actively undermining. The lone Neutral (The Asymmetric Bargainer, leaning Bearish) does not defend the stock — he objects on price, arguing the asymmetry is poor at 526.5 rather than defending the fundamentals. No voice argues the stock is cheap or the recovery is de-risked.
Key levels
Key levels · SALM
NOK · as of 2026-08-22Analyst consensus target 594.18 NOK · range 500–676
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance clusters at 537.50–540.30, where the weekly EMA50 and the monthly 50% Fibonacci retracement of the 780→305 decline converge; this is the zone price must reclaim to challenge the Stage 4 downtrend. The volume POC at 565.27 sits well overhead. Key support rests at 516.38, the weekly 61.8% Fibonacci retracement of the 627→448 swing, and at 520 the round-number psychological level. The analyst consensus target of 594.18 sits well above the resistance zone, which explains the lingering 'Buy' rating despite deteriorating revisions: the average target implies 12.9% upside, but only if the recovery materialises on schedule.
What legendary investors think
We ran SalMar ASA past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Forensic SkepticContrarian/Forensic🔴 BearishLow
Signal: EPS estimates for Q2 2026 have been cut 30% in the last 30 days, and the company has missed consensus in seven of the last eight quarters by an average of 3.68%. Conviction: Conviction is restrained because the core bear thesis rests on a single contested assumption, whether salmon spot prices disappoint relative to the forward curve, rather than on multiple independent red flags.
The Intrinsic-Value ModelerValuation/DCF🔴 BearishLow
Signal: Even under a base case that assumes a 12% revenue CAGR and operating margins recovering to 18%, the fair value lands at roughly 480 NOK, about 9% below the current quote. Conviction: Confidence is limited by the number of inputs that must be proxied rather than observed directly — beta, the Norwegian ERP, and the true sustainable ROIC are all absent from the record.
The GARP OperatorGrowth (GARP)⚫ NeutralLow
Signal: That PEG of 0.22 is a cyclical mirage: it divides a 16.6x forward multiple by a 153% one-year earnings snapback, the kind of growth rate that never sustains in a commodity protein business. Conviction: Conviction firms up because two separate, hard-to-dismiss facts point the same way — the recovery-rate illusion in the PEG and the negative trajectory of consensus revisions.
The Asymmetric BargainerContrarian/Deep Value🔴 BearishLow
Signal: The Dhandho framework rejects this setup at the first gate after simplicity: net debt at 22.1B NOK and interest coverage at 2.99x mean the downside is not limited, so the 'tails I don't lose much' premise collapses. Conviction: What holds conviction back is the absence of a clear liquidation floor — license values might be worth something, but they are illiquid and unmarked, so the true worst case is unknowable.
The Activist CatalystActivist/Capital Allocation🔴 BearishMed
Signal: This is not a business where you can underwrite cash flows five years out: salmon spot prices swing 30-50% a year on biological and supply factors, and the entire earnings recovery narrative hinges on a single volatile input. Conviction: Conviction strengthens because two separate structural weaknesses — an over-levered balance sheet and low insider ownership below 5% — reinforce the bear case without needing to predict salmon prices.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The V-shaped earnings recovery is already reflected in the forward multiple of ~16.6x, leaving little room for disappointment.
- The balance sheet is over-levered: net debt of 22.1B NOK, equity of ~20.8B, and interest coverage at a thin 2.99x create real fragility.
- Negative estimate revisions are accelerating — FY2026 EPS has been cut roughly 9% in 90 days, and Q2 estimates fell 30% in 30 days.
- The monthly chart remains in a Stage 4 downtrend with price below all key moving averages, and the 565 level represents overhead supply.
The real debate
- The Intrinsic-Value Modeler sees the stock as merely overpriced (fair value ~480, a manageable 9% gap), while the Asymmetric Bargainer sees a genuinely unfavorable payoff structure where the expected return is negative even probabilistically.
- The GARP Operator treats the PEG ratio as seductive but deceptive for a cyclical, whereas the Forensic Skeptic focuses on the serial earnings-miss pattern and treats the forward multiple itself as unreliable.
- The Activist Catalyst rejects the entire business model as too unpredictable for a concentrated long-term commitment, a more fundamental dismissal than the Intrinsic-Value Modeler's recovery-timing critique.
The question it comes down to: Can SalMar generate enough free cash flow over the next four quarters to de-lever its balance sheet before salmon spot prices or the Q2 print force a covenant or confidence crisis?
The bottom line
- Trigger to flip bearish structure: A weekly close above 540 on expanding volume would be the first credible signal that the monthly Stage 4 downtrend is transitioning, invalidating the bearish technical base.
- Earnings catalyst: The Q2 2026 report due 25 August is binary: estimates have been cut 30% in 30 days, and a miss would confirm the negative revision trend, while a beat with raised guidance could reset the recovery narrative.
- Salmon price threshold: Sustained spot prices above 85 NOK/kg would align reality with the Q4 forward curve and give the earnings recovery a factual footing; a break below 70 NOK/kg likely triggers a debt-service scare.
- Debt-reduction proof: A clear deleveraging trajectory — net debt declining toward 15B NOK within two quarters, driven by FCF rather than asset sales — would address the single biggest risk that unites all five voices.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in SALM · SALM verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated